BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34638842)

  • 21. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
    Liang H; Chen Z; Sun L
    Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.
    Yang YP; Chien Y; Chiou GY; Cherng JY; Wang ML; Lo WL; Chang YL; Huang PI; Chen YW; Shih YH; Chen MT; Chiou SH
    Biomaterials; 2012 Feb; 33(5):1462-76. PubMed ID: 22098779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation.
    Wang K; Michelakos T; Wang B; Shang Z; DeLeo AB; Duan Z; Hornicek FJ; Schwab JH; Wang X
    Cancer Lett; 2021 May; 505():37-48. PubMed ID: 33582212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
    Hsieh CH; Lin YJ; Wu CP; Lee HT; Shyu WC; Wang CC
    Clin Cancer Res; 2015 Jan; 21(2):460-70. PubMed ID: 25370472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
    Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
    Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
    Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
    Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
    Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
    Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
    Zhang M; Herion TW; Timke C; Han N; Hauser K; Weber KJ; Peschke P; Wirkner U; Lahn M; Huber PE
    Neoplasia; 2011 Jun; 13(6):537-49. PubMed ID: 21677877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.
    Zirjacks L; Stransky N; Klumpp L; Prause L; Eckert F; Zips D; Schleicher S; Handgretinger R; Huber SM; Ganser K
    Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
    Cho HR; Kumari N; Thakur N; Vu HT; Kim H; Choi SH
    Sci Rep; 2019 Nov; 9(1):16613. PubMed ID: 31719653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
    Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
    Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram.
    Sun T; Yang W; Toprani SM; Guo W; He L; DeLeo AB; Ferrone S; Zhang G; Wang E; Lin Z; Hu P; Wang X
    Cell Commun Signal; 2020 Mar; 18(1):36. PubMed ID: 32138738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.